Comparing Compass Pathways (NASDAQ:CMPS) and Ryman Healthcare (OTCMKTS:RYHTY)

Compass Pathways (NASDAQ:CMPS) and Ryman Healthcare (OTCMKTS:RYHTY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Compass Pathways and Ryman Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Ryman Healthcare	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Compass Pathways and Ryman Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1	1	10	2	2.93
Ryman Healthcare	0	0	0	0	0.00

Compass Pathways currently has a consensus target price of $21.36, suggesting a potential upside of 70.50%. Given Compass Pathways’ stronger consensus rating and higher probable upside, research analysts clearly believe Compass Pathways is more favorable than Ryman Healthcare.

Earnings and Valuation

This table compares Compass Pathways and Ryman Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86 million	($3.15)	-3.98
Ryman Healthcare	$502.59 million	2.47	-$100.65 million	N/A	N/A

Ryman Healthcare has higher revenue and earnings than Compass Pathways.

Volatility & Risk

Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Ryman Healthcare has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Institutional and Insider Ownership

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Compass Pathways beats Ryman Healthcare on 7 of the 11 factors compared between the two stocks.

About Compass Pathways

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About Ryman Healthcare

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The company's villages provide a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which offers rest homes, hospitals, dementia-level care, and respite and day care services. Its villages also provide all-weather bowling green, indoor heated swimming pool and spa, gym, internal atrium, beauty and hair salons, library, dining area, bar, lounges, croquet laws, shops, and movie theatre facilities. The company owns and operates retirement village units and care units. The company was founded in 1984 and is based in Christchurch, New Zealand.